- Home
- RDHL
as 02-21-2025 4:00pm EST
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
| Founded: | 2009 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 9.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -38.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.76 - $20.28 | Next Earning Date: | 04-07-2025 |
| Revenue: | $3,707,000 | Revenue Growth: | -89.63% |
| Revenue Growth (this year): | 224.9% | Revenue Growth (next year): | 82.69% |
Latest Redhill Biopharma Ltd. News
RDHL Breaking Stock News: Dive into RDHL Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
17 days ago
RedHill Biopharma launches trial of combination therapy for prostate cancer
MT Newswires
18 days ago
RedHill Biopharma Begins Phase 2 Study of Opaganib, Darolutamide for Advanced Prostate Cancer; Shares Rise
PR Newswire
18 days ago
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
PR Newswire
a month ago
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
PR Newswire
2 months ago
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
TipRanks
3 months ago
RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court
MT Newswires
3 months ago
RedHill Biopharma Awarded $8 Million in Legal Case Against Kukbo
PR Newswire
3 months ago
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
Compare RDHL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RDHL Redhill Biopharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.